Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE TrialBLUMENSCHEIN, George R; SAINTIGNY, Pierre; KIES, Merrill S et al.Clinical cancer research (Print). 2013, Vol 19, Num 24, pp 6967-6975, issn 1078-0432, 9 p.Article

Phase II Study of Dasatinib in Patients With Advanced Non-Small-Cell Lung CancerJOHNSON, Faye M; NEBIYOU BEKELE, B; LIPPMAN, Scott M et al.Journal of clinical oncology. 2010, Vol 28, Num 30, pp 4609-4615, issn 0732-183X, 7 p.Article

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non―Small-Cell Lung CancerHANRAHAN, Emer O; LIN, Heather Y; JOHNSON, Bruce E et al.Journal of clinical oncology. 2010, Vol 28, Num 2, pp 193-201, issn 0732-183X, 9 p.Article

Circulating Biomarkers for Vascular Endothelial Growth Factor Inhibitors in Renal Cell CarcinomaZURITA, Amado J; JONASCH, Eric; WU, Hua-Kang et al.Cancer. 2009, Vol 115, Num 10, pp 2346-2354, issn 0008-543X, 9 p., SUPConference Paper

Phase I and pharmacological study of oral 9-Aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumorsXIONG, Henry Q; TRAN, Hai T; MADDEN, Timothy L et al.Clinical cancer research. 2003, Vol 9, Num 6, pp 2066-2071, issn 1078-0432, 6 p.Article

Passive film-induced stress and mechanical properties of α-Ti in methanol solutionZHI QIN; XIAOLU PANG; YU YAN et al.Corrosion science. 2014, Vol 78, pp 287-292, issn 0010-938X, 6 p.Article

Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with PazopanibNIKOLINAKOS, Petros G; ALTORKI, Nasser; YANKELEVITZ, David et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 6, pp 2171-2179, issn 0008-5472, 9 p.Article

A Phase 2 Study of Cetuximab in Combination With Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Nonsmall Cell Lung CancerKIM, Edward S; MAUER, Ann M; WILLIAM, William N et al.Cancer. 2009, Vol 115, Num 8, pp 1713-1722, issn 0008-543X, 10 p.Article

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small-cell lung cancerHERBST, Roy S; MADDEN, Timothy L; HINTON, Leslie et al.Journal of clinical oncology. 2002, Vol 20, Num 22, pp 4440-4447, issn 0732-183X, 8 p.Article

A Phase 1 Study of Weekly Everolimus (RAD001) in Combination With Docetaxel in Patients With Metastatic Breast CancerMOULDER, Stacy; GLADISH, Gregory; RIVERA, Edgardo et al.Cancer. 2012, Vol 118, Num 9, pp 2378-2384, issn 0008-543X, 7 p.Article

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic ResistanceKOPETZ, Scott; HOFF, Paulo M; LIEU, Christopher et al.Journal of clinical oncology. 2010, Vol 28, Num 3, pp 453-459, issn 0732-183X, 7 p.Article

VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabCARBONE, David P; STUART SALMON, J; TRAN, Hai T et al.Lung cancer. 2010, Vol 69, Num 3, pp 337-340, issn 0169-5002, 4 p.Article

TRIBUTA: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerHERBST, Roy S; PRAGER, Diane; RAMIES, David et al.Journal of clinical oncology. 2005, Vol 23, Num 25, pp 5892-5899, issn 0732-183X, 8 p.Article

Phase I study of recombinant human endostatin in patients with advanced solid tumorsHERBST, Roy S; HESS, Kenneth R; ELLIS, Lee M et al.Journal of clinical oncology. 2002, Vol 20, Num 18, pp 3792-3803, issn 0732-183X, SUPArticle